Neuroscientific Biopharmaceuticals Ltd has released a press release.
Experienced Cell Therapy Executive Appointed CEO
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- StemSmart Acquisition Complete
- Previous StemSmart Studies Demonstrate Clinical Response
- NeuroScientific to Acquire Leading Stem Cell Technology
- 2024 Annual Report & Appendix 4E
- Appointment of Executive Director & FDA Pre-Ind Meeting
Later from Neuroscientific Biopharmaceuticals
- Previous StemSmart Studies Support Renal Transplantation
- 2025 Annual Report & Appendix 4E
- Fourth Patient Commences StemSmart MSC Treatment
- Trading Halt
- Successful Clinical Results Achieved under Special Access
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals